PLRZ
Polyrizon Ltd. (NASDAQ)
Healthcare — Biotechnology
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
None
$12.68
+$0.16 (+1.28%)
Sign in to add PLRZ to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $26.42M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-4.90 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -25.38% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 60.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.20 |
| 52-Week Low | $2.88 |
| 50-Day Avg | $13.95 |
| 200-Day Avg | $11.06 |
| Avg Volume | 44.6K |
| Volume | 16.3K |
Performance Analysis
NEUTRALPLRZ presents a mixed picture with both positive and negative indicators.
~
Trading at 64% of its 52-week range.
+
RSI at 60.3 shows positive momentum.
~
Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report